Intersect ENT Revenue and Competitors
Estimated Revenue & Valuation
- Intersect ENT's estimated annual revenue is currently $112.4M per year.
- Intersect ENT received $30.0M in venture funding in February 2013.
- Intersect ENT's estimated revenue per employee is $698,435
- Intersect ENT's total funding is $167.8M.
Employee Data
- Intersect ENT has 161 Employees.
- Intersect ENT grew their employee count by -8% last year.
Intersect ENT Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $20.3M | 81 | 7% | N/A | N/A |
#2 | $8.5M | 34 | 6% | N/A | N/A |
#3 | $4.5M | 18 | -10% | N/A | N/A |
#4 | $8M | 32 | -6% | N/A | N/A |
#5 | $5.3M | 21 | 0% | N/A | N/A |
#6 | $54.2M | 216 | 9% | N/A | N/A |
#7 | $12M | 48 | N/A | N/A | N/A |
#8 | $10M | 40 | 5% | N/A | N/A |
#9 | $30.1M | 120 | 22% | N/A | N/A |
#10 | $14.1M | 56 | 2% | N/A | N/A |
What Is Intersect ENT?
Intersect ENT (Nasdaq:XENT) is a medical technology company dedicated to advancing the treatment of ear, nose and throat (ENT) conditions through evidence-based innovation, providing physicians with solutions to overcome clinical challenges and improve the quality of life for patients. For additional information on the company or the products including risks and benefits please visit www.intersectENT.com
keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals
$167.8M
Total Funding
161
Number of Employees
$112.4M
Revenue (est)
-8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Intersect ENT News
Intersect ENT (NASDAQ:XENT) Stock Rating Lowered by StockNews.com. Posted by admin on Apr 26th, 2022. Share on Twitter Share on Facebook Share on LinkedIn...
Medtronic's (NYSE:MDT) planned purchase of Intersect ENT (NASDAQ:XENT) is now likely to close in May instead of this month.
September 20, 2021-Alexandria, Virginia-The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS), in partnership with Intersect ENT, Inc., launched a public education campaign that provides clinically-developed information by experts in the field aimed at helping people better unde ...
DUBLIN and MENLO PARK, Calif., Aug. 6, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it has entered into a definitive agreement with Intersect ENT (NASDAQ: XENT), a global ear, nose, and throat (ENT) medical technology leader dedicat ...
Intersect ENT said today that it hopes to raise as much as $65 million in an initial public offering of 5 million shares. Intersect, which makes drug-eluting devices designed to treat ear, nose & throat conditions, said it plans to price the shares at $11 to $13 apiece, meaning the offering cou ...
Other Companies in Menlo Park
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $26M | 163 | N/A | N/A |
#2 | $18.6M | 169 | 27% | N/A |
#3 | $42.7M | 170 | 24% | $145.6M |
#4 | $27.3M | 171 | N/A | N/A |
#5 | $47.6M | 173 | 8% | N/A |
Intersect ENT Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2008-06-06 | $20.0M | B | PTV Sciences | Article |
| 2010-11-03 | $30.0M | Undisclosed | Article | |
| 2013-02-26 | $30.0M | D | Norwest Venture Partners | Article |